Sethera Therapeutics, Inc. Press Releases - EIN Presswire

Published on August 10, 2026 - 12:00 GMT

Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program

SALT LAKE CITY, UT, UNITED STATES, August 10, 2026 /⁨EINPresswire.com⁩/ -- Salt Lake City, UT —August 10th, 2026 — Sethera Therapeutics announced that a collaborative breast cancer research project with Roswell Park Comprehensive Cancer Center has received …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on August 3, 2026 - 12:15 GMT

Sethera Therapeutics and Receptor.AI Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines

Collaboration combines Sethera's proprietary enzymatic polymacrocyclization and trillion-scale encoded screening with Receptor.AI's physics-based modeling SALT LAKE CITY, UT, UNITED STATES, August 3, 2026 /⁨EINPresswire.com⁩/ -- SALT LAKE CITY and …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on October 30, 2025 - 14:42 GMT

Sethera Therapeutics Co-Founders Named Founders of the Year by the University of Utah Innovation Awards

SALT LAKE CITY, UT, UNITED STATES, October 30, 2025 /⁨EINPresswire.com⁩/ -- Sethera Therapeutics is proud to announce that its co-founders, Dr. Vahe Bandarian and Dr. Karsten Eastman, have been honored with the Founders of the Year Award at the University …

Distribution channels: Business & Economy, Education ...

Published on October 14, 2025 - 12:00 GMT

Sethera Therapeutics Releases New Paper Introducing Enzymatic Macrocyclization Platform to Upgrade GLP 1 Peptides

SALT LAKE CITY, UT, UNITED STATES, October 14, 2025 /⁨EINPresswire.com⁩/ -- Sethera Therapeutics, a biotechnology company advancing next-generation polymacrocyclic peptide therapeutics, today announced a published study that outlines a new biocatalysis …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 25, 2025 - 17:25 GMT

Sethera Therapeutics Appoints Jeffery W. Kelly and Alexander M. Klibanov to Scientific Advisory Board

SALT LAKE CITY, UT, UNITED STATES, September 25, 2025 /⁨EINPresswire.com⁩/ -- Sethera Therapeutics, a biotechnology company advancing next-generation polymacrocyclic peptide therapeutics, today announced the appointment of two globally recognized …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...